Four controlled trials including 1448 patients (n = 383 in the experimental H + P groups and n = 1065 in the control H groups) were analyzed for the pCR rate in stage Ӏ-III HER2+ breast cancer patients [22–25]. Here, ERBB2 is linked to breast carcinoma.